← Screener · Thematic / sector
HLTHVanEck · Equity - Global Sectors · Equity · Global ex-Australia
VanEck Global Healthcare Leaders ETF
Fee p.a.
0.45%
ASX report
Fund size
A$52m
12m flow A$2.9m
Yield
0.3%
1 payments / yr
Volatility 3y
13.9%
annualised
Max DD 3y
−18.0%
all-time −28.1%
Listed
2020
10 Sept 2020 · spread 0.27%
$9k$10k$10k$11k$11k$12k$12k$13k$13k2020202120222023202420252026
Performance
Period
Total
ASX
1 month
2.5%
−0.2%
3 months
11.2%
—
6 months
4.1%
—
Year to date
−2.2%
—
1 year
4.4%
4.6%
3 years p.a.
4.9%
4.4%
5 years p.a.
−0.9%
0.0%
10 years p.a.
—
—
Since listing p.a.
3.7%
—
Total return to 4 Sept 2026, distributions reinvested, before franking. ASX figures are to 31 July 2026 and gross of franking, so they run higher for franked Australian funds.
Sharpe 3y 0.07Vol 1y 15.1%Vol 5y 14.8%Max DD 1y −18.0%Max DD 5y −27.2%Best year 21.0%60% positive years
Calendar-year returns
2021
21.0%
2022
−14.1%
2023
−1.9%
2024
10.3%
2025
9.3%
2026
−2.2%
Where the money is
Look-through exposure as at 3 Sept 2026 · 50 securities · top 10 = 27.2%
Country
United States62.0%
Japan12.2%
South Korea5.8%
Denmark4.1%
Switzerland2.6%
Israel2.2%
Finland2.1%
New Zealand2.1%
France2.0%
United Kingdom1.7%
Top holdings
Illumina IncUnited States
3.3%
Halozyme Therapeutics IncUnited States
3.1%
Arrowhead Pharmaceuticals IncUnited States
2.8%
Argenx SeUnited States
2.7%
West Pharmaceutical Services IncUnited States
2.6%
Ypsomed Holding AgSwitzerland
2.6%
Exelixis IncUnited States
2.6%
Dexcom IncUnited States
2.5%
Incyte CorpUnited States
2.5%
Merck & Co IncUnited States
2.4%
Novo Nordisk A/SDenmark
2.3%
Teva Pharmaceutical Industries LtdIsrael
2.2%
Neurocrine Biosciences IncUnited States
2.2%
Encompass Health CorpUnited States
2.2%
Amgen IncUnited States
2.2%
Top 15 of 50 holdings.
Most similar funds
Overlap is the share of the portfolio held in common, look-through. Correlation is of daily returns. High overlap means close substitutes.
Code
Fund
Fee
Overlap
Corr 3y